SLC5A2 and type 2 diabetes mellitus: In a post hoc study using 695 T2D patients inadequately controlled by metformin alone, exenatide (GLP-1 receptor agonists) and dapagliflozin (SGLT2 inhibitors) combination could notably reduce the fatty liver index and the fibrosis-4 index from baseline, suggesting the beneficial effects in improving markers of hepatic steatosis and fibrosis (172).